Skip to content
10-Q

Quarterly Report

Decoy Therapeutics Inc. DCOY

0001193125-26-214816

← back to feed
Filed
May 8, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 7, 2026 531.97K sh
Shares Diluted Q1 2026 · Mar 31, 2026 531.97K sh
Shares Diluted restated Q1 2026 · Mar 31, 2025 7.12K sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$2.89M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$1.18M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $7.82M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $10.71M
Stockholders Equity Q1 2026 · Mar 31, 2026 $3.88M
Stockholders Equity Q1 2026 · Dec 31, 2025 $5.89M
Stockholders Equity Q1 2026 · Mar 31, 2025 $61.87K
Stockholders Equity Q1 2026 · Dec 31, 2024 $1.51M
Current Liabilities Q1 2026 · Mar 31, 2026 $4.55M
Current Liabilities Q1 2026 · Dec 31, 2025 $5.17M
Total Liabilities Q1 2026 · Mar 31, 2026 $4.55M
Total Liabilities Q1 2026 · Dec 31, 2025 $5.17M
Current Assets Q1 2026 · Mar 31, 2026 $8.36M
Current Assets Q1 2026 · Dec 31, 2025 $10.99M
Total Assets Q1 2026 · Mar 31, 2026 $8.42M
Total Assets Q1 2026 · Dec 31, 2025 $11.06M
Eps Diluted Q1 2026 · Mar 31, 2026 −$4.18
Eps Diluted restated Q1 2026 · Mar 31, 2025 −$240.07
Eps Basic Q1 2026 · Mar 31, 2026 −$4.18
Eps Basic restated Q1 2026 · Mar 31, 2025 −$240.07
Sga Expense Q1 2026 · Mar 31, 2026 $1.53M
Sga Expense Q1 2026 · Mar 31, 2025 $1.64M
Rd Expense Q1 2026 · Mar 31, 2026 $749.81K
Rd Expense Q1 2026 · Mar 31, 2025 $75.53K
Net Income Q1 2026 · Mar 31, 2026 −$2.22M
Net Income Q1 2026 · Mar 31, 2025 −$1.71M
Operating Income Q1 2026 · Mar 31, 2026 −$2.28M
Operating Income Q1 2026 · Mar 31, 2025 −$1.72M